Novel therapeutic opportunities for Toxoplasma gondii, Trichomonas vaginalis, and Giardia intestinalis infections

References

• Blader IJ, Coleman BI, Chen CT, et al. Lytic cycle of Toxoplasma gondii: 15 years later. Annu Rev Microbiol. 2015;69(1):463–485.
   PubMed Web of Science ®Google Scholar
• Dubey JP. The history of Toxoplasma gondii- The first 100 years. J Eukaryotic Microbiol. 2008;55(6):467–475.
   PubMed Web of Science ®Google Scholar
• Agop-Nersesian C, Naissant B, Ben RF, et al. Rab11a-controlled assembly of the inner membrane complex is required for completion of apicomplexan cytokinesis. PLOS Pathog. 2009 5;5(1):e1000270. DOI:10.1371/journal.ppat.1000270
   PubMed Web of Science ®Google Scholar
• Ferguson DJP. Toxoplasma gondii: 1908-2008, homage to Nicolle, Manceaux and Splendore. Memórias Inst Oswaldo Cruz. 2009;104(2):133–148.
   PubMed Web of Science ®Google Scholar
• S Al Malki E. Toxoplasmosis: stages of the protozoan life cycle and risk assessment in humans and animals for an enhanced awareness and an improved socio-economic status. Saudi J Biol Sci. 2021;28(1):962–969.
   PubMed Web of Science ®Google Scholar
• Carradori S, Secci D, Bizzarri B, et al. Synthesis and biological evaluation of anti-Toxoplasma gondii activity of a novel scaffold of thiazolidinone derivatives. J Enzyme Inhib Med Chem. 2017;32(1):32. DOI:10.1080/14756366.2017.1316494
   Web of Science ®Google Scholar
• Hopper AT, Brockman A, Wise A, et al. Discovery of selective Toxoplasma gondii Dihydrofolate reductase inhibitors for the treatment of Toxoplasmosis. J Med Chem. 2019;62(3):1562–1576. DOI:10.1021/acs.jmedchem.8b01754
   PubMed Web of Science ®Google Scholar
• Stanić Ž, Fureš R. Toxoplasmosis: a global zoonosis. Veterinaria. 2020;69:31–42.
   Google Scholar
• Weiss LM, Dubey JP. Toxoplasmosis: a history of clinical observations. Int J Parasitol. 2009;39(8):895–901.
   PubMed Web of Science ®Google Scholar
• Elsheikha HM, Marra CM, Zhu XQ. Epidemiology, pathophysiology, diagnosis, and management of Cerebral Toxoplasmosis. Clin Microbiol Rev. 2020;34(1):1–28.
   Web of Science ®Google Scholar
• Di Genova BM, Wilson SK, Dubey JP, et al. Intestinal delta-6-desaturase activity determines host range for Toxoplasma sexual reproduction. bioRxiv. 2019:1–19. DOI:10.1101/688580
   Google Scholar
• Attias M, Teixeira DE, Benchimol M, et al. The life-cycle of Toxoplasma gondii reviewed using animations. Parasites Vectors. 2020 13;13(1). DOI:10.1186/s13071-020-04445-z
   PubMed Web of Science ®Google Scholar
• Black MW, Boothroyd JC. Lytic cycle of Toxoplasma gondii. Microbiol Mol Biol Rev. 2000;64(3):607–623.
   PubMed Web of Science ®Google Scholar
• Hoff EF, Carruthers VB. Is Toxoplasma egress the first step in invasion? Trends Parasitol. 2002;18(6):251–255.
   PubMed Web of Science ®Google Scholar
• Wang ZD, Liu HH, Ma ZX, et al. Toxoplasma gondii infection in immunocompromised patients: a systematic review and meta-analysis. Front Microbiol. 2017;8:1–12.
   PubMed Web of Science ®Google Scholar
• Cerutti A, Blanchard N, Besteiro S. The bradyzoite: a key developmental stage for the persistence and pathogenesis of toxoplasmosis. Pathogens. 2020;9(3):1–21.
   Web of Science ®Google Scholar
• Dubey JP, Lago EG, Gennari SM, et al. Toxoplasmosis in humans and animals in Brazil: high prevalence, high burden of disease, and epidemiology. Parasitology. 2012;139(11):1375–1424.
   PubMed Web of Science ®Google Scholar
• Mareze M, Do Nascimento Benitez A, Pérola Drulla Brandão A, et al. Socioeconomic vulnerability associated to Toxoplasma gondii exposure in southern Brazil. PLoS ONE. 2019 14;14(2):e0212375. DOI:10.1371/journal.pone.0212375
   PubMed Web of Science ®Google Scholar
• Johnson SK, Johnson PTJ. Toxoplasmosis: recent advances in understanding the link between infection and host behavior 2021. Ann Rev Anim Biosci. 2021;9(1):249–264.
   PubMedGoogle Scholar
• McAuley JB. Congenital toxoplasmosis. J Pediatric Infect Dis Soc. 2014 3;3(suppl_1):S30–35. DOI:10.1093/jpids/piu077
   PubMedGoogle Scholar
• Demar M, Hommel D, Djossou F, et al. Acute toxoplasmoses in immunocompetent patients hospitalized in an intensive care unit in French Guiana. Clin Microbiol Infect. 2012 18;18(7):E221–231. DOI:10.1111/j.1469-0691.2011.03648.x
   PubMed Web of Science ®Google Scholar
• Oz HS. Maternal and congenital toxoplasmosis, currently available and novel therapies in horizon. Front Microbiol. 2014 5;5. DOI:10.3389/fmicb.2014.00385
   Web of Science ®Google Scholar
• Furtado JM, Smith JR, Belfort R, et al. Toxoplasmosis: a global threat. J Glob Infect Dis. 2011;3(3):281–284.
   PubMedGoogle Scholar
• Wang ZD, Liu HH, Ma ZX, et al. Toxoplasma gondii infection in immunocompromised patients: a systematic review and meta-analysis. Front Microbiol. 2017 8;8. DOI:10.3389/fmicb.2017.00389
   Web of Science ®Google Scholar
• Benchimol M, Gadelha AP, de Souza W. Unusual cell structures and organelles in Giardia intestinalis and Trichomonas vaginalis are potential drug targets. Microorganisms. 2022;10(11):2176.
   PubMed Web of Science ®Google Scholar
• Schwebke JR, Burgess D. Trichomoniasis. Clin Microbiol Rev. 2004;17(4):794–803.
   PubMed Web of Science ®Google Scholar
• Pereira-Neves A, Ribeiro KC, Benchimol M. Pseudocysts in Trichomonads – new insights. Protist. 2003;154:313–329.
   PubMed Web of Science ®Google Scholar
• Menezes CB, Frasson AP, Tasca T. Trichomoniasis – are we giving the deserved attention to the most common non-viral sexually transmitted disease worldwide? Microb Cell. 2016;3(9):404–418.
   PubMed Web of Science ®Google Scholar
• Cherpes TL, Wiesenfeld HC, Melan MA, et al. The associations between pelvic inflammatory disease, Trichomonas vaginalis infection, and positive herpes simplex virus type 2 serology. Sex Trans Dis. 2006;33(12):747–752. DOI:10.1097/01.olq.0000218869.52753.c7
   PubMed Web of Science ®Google Scholar
• Silver BJ, Guy RJ, Kaldor JM, et al. Trichomonas vaginalis as a cause of perinatal morbidity: a systematic review and meta-analysis. Sex Trans Dis. 2014;41(6):369–376.
   PubMed Web of Science ®Google Scholar
• Masha SC, Cools P, Sanders EJ, et al. Trichomonas vaginalis and HIV infection acquisition: a systematic review and meta-analysis. Sex Transm Infect. 2019;95(1):36–42.
   PubMed Web of Science ®Google Scholar
• Hooshyar H, Rostamkhani P, Arbabi M, et al. Giardia lamblia infection: review of current diagnostic strategies. n.d.
   Google Scholar
• Ferreira B, Lourenço Á, Sousa MDC. Protozoa-derived extracellular vesicles on intercellular communication with special emphasis on Giardia lamblia. Microorganisms. 2022;10(12):2422.
   PubMed Web of Science ®Google Scholar
• Fekete E, Allain T, Siddiq A, et al. Giardia spp. and the gut microbiota: dangerous liaisons. Front Microbiol. 2021;11:11.
   Web of Science ®Google Scholar
• Sabin AB, Warren J Therapeutic effectiveness of certain sulfonamides on infection by an intracellular protozoan (Toxoplasma). Proceedings of the Society for Experimental Biology and Medicine 1942;51:p. 19–23. DOI:10.3181/00379727-51-13809.
   Google Scholar
• Eichenwald H. Experimental Toxoplasmosis. II. effect of sulfadiazine and antiserum on congenital Toxoplasmosis in mice. Proceedings of the Society for Experimental Biology and Medicine 1949;71:p. 45–49. DOI:10.3181/00379727-71-17074
   Google Scholar
• Eyles DE, Nell C. Synergistic effect of sulfadiazine and daraprim against experimental Toxoplasmosis in the mouse. Antibiot & Chemother. 1953;3:483–490.
   Google Scholar
• Kayhoe DE, Jacobs L, Beye HK, et al. Acquired toxoplasmosis; observations on two parasitologically proved cases treated with pyrimethamine and triple sulfonamides. N Engl J Med. 1957;257:1247–1254.
   PubMed Web of Science ®Google Scholar
• Konstantinovic N, Guegan H, Stäjner T, et al. Treatment of toxoplasmosis: current options and future perspectives. Food Waterborne Parasitol. 2019 15;15:e00036. DOI:10.1016/j.fawpar.2019.e00036
   PubMedGoogle Scholar
• Wettingfeld RF, Rowe J, Eyles DE. Treatment of toxoplasmosis with pyrimethamine (daraprim) and triple sulfonamide. Ann Intern Med. 1956;44:557–564 .
   PubMed Web of Science ®Google Scholar
• Maldonado YA, Read JS, Byington CL, et al. Diagnosis, treatment, and prevention of congenital toxoplasmosis in the United States. Pediatrics. 2017;139(2):139. DOI:10.1542/peds.2016-3860
   Web of Science ®Google Scholar
• Bennett, John E., Raphael Doiin, and Martin J. Blaser. Mandell, Douglas, and Bennett’s principles and practice of infectious diseases. Elsevier. 2015. DOI:10.1016/C2012-1-00075-6
   Google Scholar
• Dannemann B, McCutchan JA, Israelski D, et al. Treatment of toxoplasmic encephalitis in patients with AIDS: a randomized trial comparing pyrimethamine plus clindamycin to pyrimethamine plus sulfadiazine. Ann Intern Med. 1992;116(1):33–43. DOI:10.7326/0003-4819-116-1-33
   PubMed Web of Science ®Google Scholar
• Katlama C, De Wit S, O’Doherty E, et al. Pyrimethamine-clindamycin vs. pyrimethamine-sulfadiazine as acute and long-term therapy for toxoplasmic encephalitis in patients with AIDS. Clinl Infect Dis. 1996;22(2):268–275.
   PubMed Web of Science ®Google Scholar
• Fernandez-Martin J, Leport C, Morlat P, et al. Pyrimethamine-clarithromycin combination for therapy of acute Toxoplasma encephalitis in patients with AIDS. Antimicrob Agents Chemother. 1991;35(10):2049–2052.
   PubMed Web of Science ®Google Scholar
• Pfefferkorn ER, Nothnagel RF, Borotz SE. Parasiticidal effect of clindamycin on Toxoplasma gondii grown in cultured cells and selection of a drug-resistant mutant. Antimicrob Agents Chemother. 1992;36(5):1091–1096.
   PubMed Web of Science ®Google Scholar
• Blais J, Tardif C, Chamberland S. Effect of clindamycin on intracellular replication, protein synthesis, and infectivity of Toxoplasma gondii. Antimicrob Agents Chemother. 1993;37(12):2571–2577.
   PubMed Web of Science ®Google Scholar
• Camps M, Arrizabalaga G, Boothroyd J. An rRNA mutation identifies the apicoplast as the target for clindamycin in Toxoplasma gondii. Mol Microbiol. 2002;43(5):1309–1318.
   PubMed Web of Science ®Google Scholar
• Chang HR, Pechere JCF. Activity of spiramycin against Toxoplasma gondii in vitro, in experimental infections and in human infection. J Antimicrob Chemother. 1988;22(Supplement_B):87–92.
   PubMedGoogle Scholar
• Alday PH, Doggett JS. Drugs in development for toxoplasmosis: advances, challenges, and current status. Drug Des Devel Ther. 2017;11:273–293.
   PubMed Web of Science ®Google Scholar
• Araujo FG, Shepard RM, Remington JS. In vivo activity of the macrolide antibiotics azithromycin, roxithromycin and spiramycin against Toxoplasma gondii. Eur J Clin Microbiol Infect Dis. 1991;10(6):519–524.
   PubMed Web of Science ®Google Scholar
• Weiss LM, Dubey Jitender P. Toxoplasmosis: a history of clinical observations. Int J Parasitol. 2009;39(8):895–901.
   PubMed Web of Science ®Google Scholar
• Couvreur J, Desmonts G, Thulliez P. Prophylaxis of congenital toxoplasmosis. Effects of spiramycin on placental infection. J Antimicrob Chemother. 1988;22(Supplement_B):193–200.
   PubMedGoogle Scholar
• Muzny CA, Van Gerwen OT, Legendre D. Secnidazole: a treatment for trichomoniasis in adolescents and adults. Expert Rev Anti Infect Ther. 2022;20(8):1067–1076.
   PubMed Web of Science ®Google Scholar
• Kissinger P. Epidemiology and Treatment of Trichomoniasis. Curr Infect Dis Rep. 2015;17(6):17.
   Web of Science ®Google Scholar
• Robinson SC. Trichomonal vaginitis resistant to metronidazole. Can Med Assoc J. 1962;86(14):665.
   PubMed Web of Science ®Google Scholar
• Hashemi N, Ommi D, Kheyri P, et al. A review study on the anti-trichomonas activities of medicinal plants. Int J Parasitol Drugs Drug Resist. 2021;15:92–104.
   PubMed Web of Science ®Google Scholar
• Riches A, Hart CJS, Trenholme KR, et al. Anti-giardia drug discovery: current status and gut feelings. J Med Chem. 2020;63(22):13330–13354.
   PubMed Web of Science ®Google Scholar
• Page MJ, McKenzie JE, Bossuyt PM, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. J Clin Epidemiol. 2021;134:178–189.
   PubMed Web of Science ®Google Scholar
• Guglielmi P, Mathew B, Secci D, et al. Chalcones: unearthing their therapeutic possibility as monoamine oxidase B inhibitors. Eur J Med Chem. 2020;205:112650.
   PubMed Web of Science ®Google Scholar
• Central South University. Chalcone derivative, preparation method thereof and application thereof in toxoplasma gondii resistance. CN110963932A. 2019.
   Google Scholar
• Shanghai Veterinary Research Institute (SHVRI). Application of quinoxaline-1,4-dioxide compounds in Anti-Toxoplasma gondii infection. CN110269859A. 2019.
   Google Scholar
• Ufermann CM, Müller F, Frohnecke N, et al. Toxoplasma gondii plaque assays revisited: improvements for ultrastructural and quantitative evaluation of lytic parasite growth. Exp Parasitol. 2017;180:19–26.
   PubMed Web of Science ®Google Scholar
• Li HY, Yang JB, Li WF, et al. In vivo hepatotoxicity screening of different extracts, components, and constituents of polygoni multiflori thunb. in zebrafish (Danio rerio) larvae. Biomed Pharmacother. 2020;131:110524.
   PubMed Web of Science ®Google Scholar
• Kim WR, Flamm SL, Di Bisceglie AM, et al. Serum activity of alanine aminotransferase (ALT) as an indicator of health and disease. Hepatology. 2008;47(4):1363–1370.
   PubMed Web of Science ®Google Scholar
• Mateos R, Lecumberri E, Ramos S, et al. Determination of malondialdehyde (MDA) by high-performance liquid chromatography in serum and liver as a biomarker for oxidative stress. Application to a rat model for hypercholesterolemia and evaluation of the effect of diets rich in phenolic antioxidants from fruits. J Chromatogr B Analyt Technol Biomed Life Sci. 2005;827(1):76–82.
   PubMed Web of Science ®Google Scholar
• Washington University, The Broad Institute, Inc., President and fellows of Harvard College. Treatment of infections of Toxoplasma gondii and closely related parasites. WO2020061167A1. 2019.
   Google Scholar
• Carme B, Bissuel F, Ajzenberg D, et al. Severe acquired toxoplasmosis in immunocompetent adult patients in French Guiana. J Clin Microbiol. 2002;40(11):4037–4044. DOI:10.1128/JCM.40.11.4037-4044.2002
   PubMed Web of Science ®Google Scholar
• Application filed by Washington University, the Broad Institute, Inc. compounds and methods for the treatment of Toxoplasma gondii infection. WO2019232417A1. 2019.
   Google Scholar
• Sasai M, Pradipta A, Yamamoto M. Host immune responses to Toxoplasma gondii. Int Immunol. 2018;30(3):113–119.
   PubMed Web of Science ®Google Scholar
• Graber JJ, Dhib-Jalbut S. Interferons. Encyclopedia of the neurological sciences. Elsevier Inc.; 2014; p. 718–723. DOI:10.1016/B978-0-12-385157-4.00182-2
   Google Scholar
• Hamming OJ, Henrik Gad H, Paludan S, et al. Lambda interferons: new cytokines with old functions. Pharmaceuticals. 2010;3(4):795–809.
   Google Scholar
• Casazza RL, Lazear HM, Miner JJ. Protective and pathogenic effects of interferon signaling during pregnancy. Viral Immunol. 2020;33(1):3–11.
   PubMed Web of Science ®Google Scholar
• Walter MR. The role of structure in the biology of interferon signaling. Front Immunol. 2020;11:11.
   PubMed Web of Science ®Google Scholar
• Brias SG, Marsden M, Forbester J, et al. Interferon lambda is required for interferon gamma-expressing NK cell responses but does not afford antiviral protection during acute and persistent murine cytomegalovirus infection. PLoS ONE. 2018 13;13(5):e0197596. DOI:10.1371/journal.pone.0197596
   PubMed Web of Science ®Google Scholar
• Nurzadeh M, Ghalandarpoor-Attar SM, Ghalandarpoor-Attar SN, et al. The role of interferon (IFN)-γ in extravillous trophoblast cell (EVT) invasion and preeclampsia progression. Reprod Sci. Reproductive Sciences 20222022. DOI:10.1007/s43032-022-01110-x
   PubMed Web of Science ®Google Scholar
• Pfefferkorn ER Interferon y blocks the growth of Toxoplasma gondii in human fibroblasts by inducing the host cells to degrade tryptophan (tryptophan/kynurenine/N-formylkynurenine). 81. 1984.
   Google Scholar
• Suzuki Y, Orellana MA, Schreiber RD, et al. Interferon-γ: the major mediator of resistance against Toxoplasma gondii. Science. 1979;240(4851):516–518.
   Google Scholar
• Tobin CM, Knoll LJ, Adams JH. A patatin-like protein protects Toxoplasma gondii from degradation in a nitric oxide-dependent manner. Infect Immun. 2012;80(1):55–61.
   PubMed Web of Science ®Google Scholar
• Krishnan A, Soldati-Favre D. Amino acid metabolism in apicomplexan parasites. Metabolites. 2021;11(2):1–17.
   Web of Science ®Google Scholar
• University of Chicago Northwestern University. Inactivators of Toxoplasma gondii ornithine aminotransferase for treating toxoplasmosis and malaria. US10632088B2. 2020.
   Google Scholar
• Burke JR, Silverman RB. Mechanism of inactivation of-aminobutyric acid aminotransferase by 4-amino-5-hexynoic acid (7-ethynyl GABAY. J Am Chem Soc. 1991;113(24):9329–9340.
   Web of Science ®Google Scholar
• Sivashanmugam M, Jaidev J, Umashankar V, et al. Ornithine and its role in metabolic diseases: an appraisal. Biomed Pharmacother. 2017;86:185–194.
   PubMed Web of Science ®Google Scholar
• Pan Y, Gerasimov MR, Kvist T, et al. (1S, 3S)-3-Amino-4-difluoromethylenyl-1-cyclopentanoic Acid (CPP-115), a Potent γ-Aminobutyric Acid Aminotransferase Inactivator for the Treatment of Cocaine Addiction. J Med Chem. 2012 1;55(1):357–366. DOI:10.1021/jm201231w
   PubMed Web of Science ®Google Scholar
• Matsui Y, Deguchi T. Effects of gabaculine, a new potent inhibitor of gamma-aminobutyrate transaminase, on the brain gamma-aminobutyrate content and convulsions in mice. Life Sci. 1977;20(7):1291–1295.
   PubMed Web of Science ®Google Scholar
• Rutaganira FU, Barks J, Dhason MS, et al. Inhibition of calcium dependent protein kinase 1 (CDPK1) by pyrazolopyrimidine analogs decreases establishment and reoccurrence of central nervous system disease by Toxoplasma gondii. J Med Chem. 2017;60(24):9976–9989. DOI:10.1021/acs.jmedchem.7b01192
   PubMed Web of Science ®Google Scholar
• Vidadala RSR, Rivas KL, Ojo KK, et al. Development of an orally available and central nervous system (CNS) penetrant Toxoplasma gondii calcium-dependent protein kinase 1 (TgCDPK1) inhibitor with minimal human ether-a-go-go-related gene (hERG) activity for the treatment of Toxoplasmosis. J Med Chem. 2016;59(13):6531–6546. DOI:10.1021/acs.jmedchem.6b00760
   PubMed Web of Science ®Google Scholar
• Hulverson MA, Bruzual I, Mcconnell EV, et al. Pharmacokinetics and in vivo efficacy of pyrazolopyrimidine, pyrrolopyrimidine, and 5-aminopyrazole-4-carboxamide bumped kinase inhibitors against Toxoplasmosis. J Infect Dis. 2019;219(9):1464–1473. DOI:10.1093/infdis/jiy664
   PubMed Web of Science ®Google Scholar
• Janetka JW, Hopper AT, Yang Z, et al. optimizing pyrazolopyrimidine inhibitors of calcium dependent protein kinase 1 for treatment of acute and Chronic Toxoplasmosis. J Med Chem. 2020;63(11):6144–6163. DOI:10.1021/acs.jmedchem.0c00419
   PubMed Web of Science ®Google Scholar
• Moine E, Moiré N, Dimier-Poisson I, et al. Imidazo[1,2-b]pyridazines targeting Toxoplasma gondii calcium-dependent protein kinase 1 decrease the parasite burden in mice with acute toxoplasmosis. Int J Parasitol. 2018;48(7):561–568. DOI:10.1016/j.ijpara.2017.12.006
   PubMed Web of Science ®Google Scholar
• Montazeri M, Sharif M, Sarvi S, et al. A systematic review of in vitro and in vivo activities of anti-toxoplasma drugs and compounds (2006–2016). Front Microbiol. 2017 8;8. DOI:10.3389/fmicb.2017.00025
   Google Scholar
• Deng Y, Wu T, Zhai SQ, et al. Recent progress on anti-Toxoplasma drugs discovery: design, synthesis and screening. Eur J Med Chem. 2019;183:183.
   Web of Science ®Google Scholar
• University of Washington. Compositions and methods for treating toxoplasmosis, cryptosporidiosis and other apicomplexan protozoan related diseases. CA2974702A1. 2019.
   Google Scholar
• University of Washington Center for Commercialization. Compositions and methods for treating toxoplasmosis, cryptosporidiosis, and other apicomplexan protozoan related diseases. US11247972B2. 2020.
   Google Scholar
• University of Washington Center for Commercialization. 5-aminopyrazole-4-carboxamide inhibitors of CDPK1 from T. gondii and C parvum. US2016090362A1. 2016.
   Google Scholar
• Guglielmi P, Secci D. Treatment of Toxoplasmosis: an insight on epigenetic drugs. 2022; p. 293–319. DOI:10.1007/7355_2021_142
   Google Scholar
• Darkin-Rattray SJ, Gurnett AM, Myers RW, et al. Apicidin: a novel antiprotozoal agent that inhibits parasite histone deacetylase. Proc. Natl. Acad. Sci. USA. 1996;93(23):13143–13147.
   PubMed Web of Science ®Google Scholar
• Centre National de la Recherche Scientifique (CNRS), Universite de Montpellier I, Institut de Recherche pour le Developpement IRD. New compounds for the treatment and/or prevention of parasitic diseases and method of production of thereof. US2019040004A1. 2018.
   Google Scholar
• McFadden DC, Seeber F, Boothroyd JC. Use of Toxoplasma gondii expressing β-galactosidase for colorimetric assessment of drug activity in vitro. Antimicrob Agents Chemother. 1997;41(9):1849–1853.
   PubMed Web of Science ®Google Scholar
• Jones-Brando L, Torrey EF, Yolken R. Drugs used in the treatment of schizophrenia and bipolar disorder inhibit the replication of Toxoplasma gondii. Schizophr Res. 2003;62(3):237–244.
   PubMed Web of Science ®Google Scholar
• Obihiro University of Agriculture and Veterinary Medicine NUC. Histone deacetylase inhibitor having antiprotozoal action. JP2019038749A. 2017.
   Google Scholar
• Murakoshi F, Bando H, Sugi T, et al. Nullscript inhibits cryptosporidium and Toxoplasma growth. Int J Parasitol Drugs Drug Resist. 2020;14:159–166.
   PubMed Web of Science ®Google Scholar
• Council of Scientific and Industrial Research CSIR. Silicon incorporated quinolines with anti-malarial and anti-toxoplasmosis activity. US10550135B2. 2017.
   Google Scholar
• Council of Scientific and Industrial Research CSIR. Silicon based cyclic compounds and pharmaceutical compositions for treating malaria and toxoplasmosis. US10562922B2. 2017.
   Google Scholar
• Shandong University. Novel thiazole derivatives, and preparation method and application thereof. CN106632133A. 2016.
   Google Scholar
• Gill J, Sharma A. Prospects of halofuginone as an antiprotozoal drug scaffold. Drug Discov Today. 2022;27(9):2586–2592.
   PubMed Web of Science ®Google Scholar
• Chongqing Academy of Animal Sciences. Febrifugine derivatives and preparation method and application thereof. CN111100079A. 2019.
   Google Scholar
• Wang G, Ge L, Liu T, et al. The therapeutic potential of arctigenin against multiple human diseases: a mechanistic review. Phytomedicine. 2023;110:110.
   Web of Science ®Google Scholar
• Affiliated Hospital Of Inner Mongolia University For Nationalities. Arctiin metaclass compound and its preparation method and application. CN108863994A. 2018.
   Google Scholar
• Affiliated Hospital Of Inner Mongolia University For Nationalities. Compound, preparation method and purposes based on arctigenin. CN108997268A. 2018.
   Google Scholar
• Affiliated Hospital Of Inner Mongolia University For Nationalities. Arctiin metaclass compound, preparation method and purposes. CN109053701A. 2018.
   Google Scholar
• Affiliated Hospital Of Inner Mongolia University For Nationalities. Compound and its preparation method and application based on arctigenin. CN108640891A. 2018.
   Google Scholar
• Adeyemi OS, Molefe NI, Awakan OJ, et al. Metal nanoparticles restrict the growth of protozoan parasites. Artif Cells Nanomed Biotechnol. 2018;46(sup3):S86–94. DOI:10.1080/21691401.2018.1489267
   PubMed Web of Science ®Google Scholar
• Obihiro University of Agriculture and Veterinary Medicine NUC. Anti-toxoplasma agent and medicine containing the same. JP2018177663A. 2017.
   Google Scholar
• Ashburn TT, Thor KB. Drug repositioning: identifying and developing new uses for existing drugs. Nat Rev Drug Discov. 2004;3(8):673–683.
   PubMed Web of Science ®Google Scholar
• Pushpakom S, Iorio F, Eyers PA, et al. Drug repurposing: progress, challenges and recommendations. Nat Rev Drug Discov. 2018;18(1):41–58. DOI:10.1038/nrd.2018.168
   PubMed Web of Science ®Google Scholar
• Hamie M, Najm R, Deleuze-Masquefa C, et al. Imiquimod targets Toxoplasmosis through modulating host toll-like receptor-MyD88 signaling. Front Immunol. 2021;12:12.
   Web of Science ®Google Scholar
• Zaki L, Ghaffarifar F, Sharifi Z, et al. Effect of imiquimod on Tachyzoites of Toxoplasma gondii and infected macrophages in vitro and in BALB/c mice. Front Cell Infect Microbiol. 2020 10;10. DOI:10.3389/fcimb.2020.00387
   PubMed Web of Science ®Google Scholar
• Shandong University. Application of the tipranavir in the drug that preparation inhibits toxoplasma growth. CN110302199A. 2019.
   Google Scholar
• Shandong University. Application of tenofovir disoproxil fumarate in the preparation of drugs for inhibiting the growth of Toxoplasma gondii. CN110302206A. 2019.
   Google Scholar
• Shandong University. Application of Elvitegravir in the preparation of drugs for inhibiting the growth of Toxoplasma gondii, CN110302200A_Original_document_20221117164439, n.d.
   Google Scholar
• Maeda K, Das D, Kobayakawa T, et al. Discovery and development of Anti-HIV therapeutic agents: progress towards Improved HIV medication. Curr Top Med Chem. 2019;19(18):1621–1649.
   PubMed Web of Science ®Google Scholar
• Basavaraju A. Toxoplasmosis in HIV infection: an overview. Trop Parasitol. 2016;6(2):129–135.
   PubMedGoogle Scholar
• Wenzhou Medical University. A kind of screening of micromolecular inhibitor that can suppress infection of Toxoplasma gondii propagation and application process. CN107884587A. 2017.
   Google Scholar
• Wenzhou Medical University. Application of a small molecule inhibitor for preparing Toxoplasma gondii proliferation. CN108057037A. 2017.
   Google Scholar
• Liu S, Wu M, Hua Q, et al. Two old drugs, NVP-AEW541 and GSK-J4, repurposed against the Toxoplasma gondii RH strain. Parasites Vectors. 2020 13;13(1). DOI:10.1186/s13071-020-04094-2
   Web of Science ®Google Scholar
• Dongyang Peoples Hospital. Application of a small molecule inhibitor capable of inhibiting the proliferation of Toxoplasma gondii. CN114788830A. 2022.
   Google Scholar
• Tasso B, Spallarossa A, Russo E, et al. The development of btk inhibitors: a five-year update. Molecules. 2021 26;26(23):7411. DOI:10.3390/molecules26237411
   PubMed Web of Science ®Google Scholar
• Lanzhou Institute of Animal Husbandry and Veterinary Medicine CAAS. Application of aminothiazole compounds in preparation of medicine for treating Toxoplasma gondii infection diseases. CN113509468A. 2021.
   Google Scholar
• Lanzhou Institute of Animal Husbandry and Veterinary Medicine CAAS. Application of quinoline compound broxaldine in inhibiting activity of Toxoplasma gondii infection diseases. CN113069452A. 2021.
   Google Scholar
• Lanzhou Institute of Animal Husbandry and Veterinary Medicine CAAS. Application of hycanthone in preparation of medicine for treating Toxoplasma gondii infection diseases. CN113398118A. 2021.
   Google Scholar
• Lanzhou Institute of Animal Husbandry and Veterinary Medicine CAAS. Application of niclosamide in treatment of Toxoplasmosis. CN110478356A. 2019.
   Google Scholar
• Lanzhou Institute of Animal Husbandry and Veterinary Medicine CAAS. Application of myrislignan in treating Toxoplasmosis. CN110876739A. 2019.
   Google Scholar
• Lanzhou Institute of Animal Husbandry and Veterinary Medicine CAAS. Application of octyl gallate in preparation of medicine for preventing and/or treating Toxoplasmosis. CN114042060A. 2021.
   Google Scholar
• Meissner A, Boshoff HI, Vasan M, et al. Structure–activity relationships of 2-aminothiazoles effective against Mycobacterium tuberculosis. Bioorg Med Chem. 2013;21(21):6385–6397.
   PubMed Web of Science ®Google Scholar
• Gentles RG, Grant-Young K, Hu S, et al. Initial SAR studies on apamin-displacing 2-aminothiazole blockers of calcium-activated small conductance potassium channels. Bioorg Med Chem Lett. 2008;18(19):5316–5319. DOI:10.1016/j.bmcl.2008.08.023
   PubMed Web of Science ®Google Scholar
• Celgene corp; Zoetis llc. Heterocyclic compounds and their use for treatment of helminthic infections and diseases. WO2020219871A1. 2020.
   Google Scholar
• Gangadhar Sharma CS. Effect of broxyquinoline and broxaldine in leprosy. Lancet. 1975;305(7903):405.
   Google Scholar
• Pashov D, Simeonov SP, Drumev D, et al. Toxicity of hydroxyquinoline derivatives. Vet Med Nauki. 1980;17(3):118–123.
   PubMedGoogle Scholar
• Murata Y, Sugi T, Weiss LM, et al. Identification of compounds that suppress Toxoplasma gondii tachyzoites & bradyzoites. PLoS ONE. 2017;12(6):12.
   Web of Science ®Google Scholar
• Zhang JL, Si HF, Shang XF, et al. New life for an old drug: in vitro and in vivo effects of the anthelmintic drug niclosamide against Toxoplasma gondii RH strain. Int J Parasitol Drugs Drug Resist. 2019;9:27–34.
   PubMed Web of Science ®Google Scholar
• Katz M. Anthelmintics. Drugs. 1986;32(4):358–371.
   PubMedGoogle Scholar
• The Catholic University Industry-University Cooperation Foundation. Composition for preventing and treating Toxoplasma gondii infection comprising dacomitinib. KR101508610B1. 2015.
   Google Scholar
• The Catholic University Industry-University Cooperation Foundation. Composition for preventing and treating Toxoplasma gondii infection comprising afatinib. KR101508611B1. 2015.
   Google Scholar
• The Catholic University Industry-University Cooperation Foundation. Composition for preventing and treating Toxoplasma gondii infection comprising crizotinib. KR101538385B1. 2015.
   Google Scholar
• The Catholic University Industry-University Cooperation Foundation. Composition for preventing and treating Toxoplasma gondii infection comprising pelitinib. KR20150027404A. 2015.
   Google Scholar
• The Catholic University Industry-University Cooperation Foundation. Pharmaceutical composition for prevention or treatment of toxoplasmosis, comprising anti-non-small cell lung cancer agent as active ingredient. WO2015030504A1. 2015.
   Google Scholar
• Kim YH, Bhatt L, Ahn HJ, et al. Suppressors for human epidermal growth factor receptor 2/4 (HER2/4): a new family of anti-toxoplasmic agents in ARPE-19 cells. Korean J Parasitol. 2017;55(5):491–503.
   PubMed Web of Science ®Google Scholar
• Kalogeropoulos D, Sakkas H, Mohammed B, et al. Ocular toxoplasmosis: a review of the current diagnostic and therapeutic approaches. Int Ophthalmol. 2022;42(1):295–321. DOI:10.1007/s10792-021-01994-9
   PubMed Web of Science ®Google Scholar
• The Catholic University Industry-University Cooperation Foundation. c-Met pharmaceutical composition comprising c-Met kinase inhibitor as active ingredient for preventing or treating Toxoplasma gondii. KR102304573. 2020.
   Google Scholar
• Swale C, Bellini V, Bowler MW, et al. Altiratinib blocks Toxoplasma gondii and Plasmodium falciparum development by selectively targeting a spliceosome kinase. Sci Trans Med. 2022;14(656).
   PubMed Web of Science ®Google Scholar
• Liu Y, Li Y, Wang Y, et al. Recent progress on vascular endothelial growth factor receptor inhibitors with dual targeting capabilities for tumor therapy. J Hematol Oncol. 2022 15;15(1). DOI:10.1186/s13045-022-01310-7
   Web of Science ®Google Scholar
• The Catholic University Industry-University Cooperation Foundation. VEGFR2 pharmaceutical composition comprising VEGFR2 inhibitor as active ingredient for preventing or treating Toxoplasma gondii. KR102301217B1. 2020.
   Google Scholar
• Obihiro University of Agriculture and Veterinary Medicine NUC. Anti-Toxoplasma gondii agent. JP2019077633A. 2017.
   Google Scholar
• Adeyemi OS, Sugi T, Han Y, et al. Screening of chemical compound libraries identified new Anti-Toxoplasma gondii agents. Parasitol Res. 2018;117(2):355–363.
   PubMed Web of Science ®Google Scholar
• Obihiro University of Agriculture and Veterinary Medicine NUC. Anti-Toxoplasma agent. JP2018035079A. 2016.
   Google Scholar
• Xu S, Liu P. Tanshinone II-A: new perspectives for old remedies. Expert Opin Ther Pat. 2013;23(2):149–153.
   PubMed Web of Science ®Google Scholar
• Spano M, Di Matteo G, Ingallina C, et al. Modulatory properties of food and nutraceutical components targeting NLRP3 inflammasome activation. Nutrients. 2022;14(3):14. DOI:10.3390/nu14030490
   Web of Science ®Google Scholar
• Freund RRA, Gobrecht P, Fischer D, et al. Advances in chemistry and bioactivity of parthenolide. Nat Prod Rep. 2020;37(4):541–565.
   PubMed Web of Science ®Google Scholar
• Wuhan Polytechnic University. Application of parthenolide in preparation of anti-Toxoplasma gondii. drugs CN110179789A. 2019.
   Google Scholar
• Nantong University. New application of IFN-lambda in Toxoplasma gondii infection. CN111494610A. 2020.
   Google Scholar
• Nantong University. New use of IFN-lambda 3 in Toxoplasma gondii infection. CN111407883A. 2020.
   Google Scholar
• Nantong University. New application of IFN-lambda 2 in Toxoplasma gondii infection. CN111494609A. 2020.
   Google Scholar
• Liu HY, Liu ZK, Chao H, et al. High-dose interferon-γ promotes abortion in mice by suppressing treg and Th17 polarization. J Interferon Cytokine Res. 2014;34(5):394–403. DOI:10.1089/jir.2013.0062
   PubMed Web of Science ®Google Scholar
• Li ZY, Chao HH, Liu HY, et al. IFN-γ induces aberrant CD49b+ NK cell recruitment through regulating CX3CL1: a novel mechanism by which IFN-γ provokes pregnancy failure. Cell Death Dis. 2014 5. DOI:10.1038/cddis.2014.470
   Web of Science ®Google Scholar
• Herkiloglu D, Gokce S, Cevik O. Relationship of interferon regulator factor 5 and interferon‑γ with missed abortion. Exp Ther Med. 2022 23;23(5). DOI:10.3892/etm.2022.11283
   Web of Science ®Google Scholar
• Yockey LJ, Iwasaki A. Interferons and proinflammatory cytokines in pregnancy and fetal development. Immunity. 2018;49(3):397–412.
   PubMed Web of Science ®Google Scholar
• Ku CW, Ong LS, Goh JP, et al. Defects in protective cytokine profiles in spontaneous miscarriage in the first trimester. F&S Sci. 2022;4(1):36–46. DOI:10.1016/j.xfss.2022.09.003
   PubMedGoogle Scholar
• Murphy SP, Tayade C, Ashkar AA, et al. Interferon gamma in successful pregnancies. Biol Reprod. 2009;80(5):848–859.
   PubMed Web of Science ®Google Scholar
• Xu X, Zheng G, Ren Y, et al. A novel 2B4 receptor leads to worse pregnancy outcomes by facilitating TNF-α and IFN-γ production in dNK cells during Toxoplasma gondii infection. Parasites Vectors. 2022 15;15(1). DOI:10.1186/s13071-022-05455-9
   Web of Science ®Google Scholar
• Wang L, Wang YJ, Liu YY, et al. In vitro potential of lycosin-I as an alternative antimicrobial drug for treatment of multidrug-resistant Acinetobacter baumannii infections. Antimicrob Agents Chemother. 2014;58(11):6999–7002. DOI:10.1128/AAC.03279-14
   PubMed Web of Science ®Google Scholar
• Shen H, Xie Y, Ye S, et al. Spider peptide toxin lycosin-I induces apoptosis and inhibits migration of prostate cancer cells. Exp Biol Med. 2018;243(8):725–735.
   Web of Science ®Google Scholar
• Central South University. Application of polypeptide Lycosin-I in preparing anti-inflammatory and Toxoplasma gondii-preventing drug. CN107496904A. 2017.
   Google Scholar
• Tang Y, Hou S, Li X, et al. Anti-parasitic effect on Toxoplasma gondii induced by a spider peptide lycosin-I. Exp Parasitol. 2019;198:17–25.
   PubMed Web of Science ®Google Scholar
• Lanzhou Institute of Animal Husbandry and Veterinary Medicine CAAS. Use of sabinene in preparing medicine for killing or preventing parasitic diseases. CN112402401A. 2020.
   Google Scholar
• Lanzhou Institute of Animal Husbandry and Veterinary Medicine CAAS. Application of naringenin and naringenin composition in preparation of medicine for treating or preventing toxoplasmosis. CN112843046A. 2021.
   Google Scholar
• Lanzhou Institute of Animal Husbandry and Veterinary Medicine CAAS. Method for treating toxoplasmosis by using isoflavonoid compound glabridin. CN113197888A. 2021.
   Google Scholar
• Ningbo University. Application of licarin-B and composition thereof in preparation of medicine for treating or preventing toxoplasmosis. CN113230248A. 2021.
   Google Scholar
• Zhang J, Si H, Lv K, et al. Licarin-B exhibits activity against the Toxoplasma gondii RH strain by damaging mitochondria and activating autophagy. Front Cell Dev Biol. 2021;9. DOI:10.3389/fcell.2021.684393.
   Web of Science ®Google Scholar
• Yanbian University. Application of coixol in preparation of medicine for preventing and treating toxoplasmosis. CN114522161A. 2021.
   Google Scholar
• Shen X-Y, Lu J-M, Lu Y-N, et al. Coixol ameliorates Toxoplasma gondii infection-induced lung injury by interfering with T. gondii HSP70/TLR4/NF-κB signaling pathway. Int Immunopharmacol. 2023;118:110031.
   PubMed Web of Science ®Google Scholar
• Guangxi University. Application of piceatannol in resisting toxoplasma infection. CN114917209A. 2022.
   Google Scholar
• Shi D, Zhang X, Song X, et al. The Anti-Toxoplasma activity of the plant natural phenolic compound piceatannol. n.d.
   Google Scholar
• Zhang J, Si H, Li B, et al. Myrislignan exhibits activities against Toxoplasma gondii RH strain by triggering mitochondrial dysfunction. Front Microbiol. 2019 10;10. DOI:10.3389/fmicb.2019.02152
   Web of Science ®Google Scholar
• Lanzhou Institute of Animal Husbandry and Veterinary Medicine CAAS. Application of traditional Chinese medicine monomer licochalcone a in treating toxoplasmosis. CN110507639A. 2019.
   Google Scholar
• Si H, Xu C, Zhang J, et al. Licochalcone A: an effective and low-toxicity compound against Toxoplasma gondii in vitro and in vivo. Int J Parasitol Drugs Drug Resist. 2018;8(2):238–245. DOI:10.1016/j.ijpddr.2018.02.006
   PubMed Web of Science ®Google Scholar
• Guglielmi P, Pontecorvi V, Rotondi G. Natural compounds and extracts as novel antimicrobial agents. Expert Opin Ther Pat. 2020;30(12):30.
   Web of Science ®Google Scholar
• Ahmad A, Husain A, Mujeeb M, et al. A review on therapeutic potential of Nigella sativa: a miracle herb. Asian Pac J Trop Biomed. 2013;3(5):337–352. DOI:10.1016/S2221-1691(13)60075-1
   PubMedGoogle Scholar
• Ijaz H, Tulain UR, Qureshi J, et al. Nigella sativa (Prophetic medicine): a review. 2017;30.
   Google Scholar
• Mady RF, El-Hadidy W, Elachy S. Effect of Nigella sativa oil on experimental toxoplasmosis. Parasitol Res. 2016;115(1):379–390.
   PubMed Web of Science ®Google Scholar
• Rayan HZ, Wagih HM, Atwa MM. Efficacy of black seed oil from Nigella sativa against murine infection with cysts of Me49 strain of Toxoplasma gondii. PUJ. 2011;4:165–176.
   Google Scholar
• Baris D. The anti-cancerous, antiparasite (Toxoplasma gondii (protozoon) and antimicrobial effect and dosage of nigella (Nigella sativa) extract. WO2016108775A1. 2016.
   Google Scholar
• Baris D. Anti-cancerous, antiparasite (Toxoplasma gondii (protozon) and antimicrobial effect and dosage of ginger (Zingiber officinale). extractUS20170348374A1. 2017.
   Google Scholar
• Wonkwang University Industry-University Cooperation Foundation. A composition comprising the extract of Suaeda maritima showing anti-toxoplasma activity. KR20150073740A. 2015.
   Google Scholar
• Wonkwang University Industry-University Cooperation Foundation. A composition comprising the extract of Plantago asiatica showing anti-toxoplasma activity. KR101710588B1. 2015.
   Google Scholar
• Han S, Zhi LL, Jiang SS. Daphne giraldii Nitsche (Thymelaeaceae): phytochemistry, pharmacology and medicinal uses. Phytochemistry. 2020:171. DOI:10.1016/j.phytochem.2019.112231
   Web of Science ®Google Scholar
• Yanbian University. Daphne giraldii extract submicron emulsion preparation for treating toxoplasmosis and preparation method thereof. CN111671825A. 2020.
   Google Scholar
• Rongcheng Fei Chuang Technology Co Ltd. Traditional Chinese medicine composition for killing Toxoplasma gondii. CN107823518A. 2017.
   Google Scholar
• Inst Politecnico Nacional. Use of novel trichomonacidal molecules. MX2016013109A. 2016.
   Google Scholar
• Inst Politecnico Nacional. Use of trichomonacidal molecules. MX2016013111A. 2016.
   Google Scholar
• Benítez-Cardoza CG, Brieba LG, Arroyo R, et al. Triosephosphate isomerase as a therapeutic target against trichomoniasis. Mol Biochem Parasitol. 2021;246:111413.
   PubMed Web of Science ®Google Scholar
• Föllmann W, Degen G, Oesch F, et al. Ames Test. Brenner’s Encycl of Genet. Second. 2013:104–107. DOI:10.1016/B978-0-12-374984-0.00048-6
   Google Scholar
• Fonseca-Berzal C, Ibáñez-Escribano A, Vela N, et al. Antichagasic, Leishmanicidal, and Trichomonacidal activity of 2-Benzyl-5-nitroindazole-derived amines. ChemMedchem. 2018;13(12):1246–1259. DOI:10.1002/cmdc.201800084
   PubMed Web of Science ®Google Scholar
• Univ Madrid Complutense; Consejo Superior De Inventigaciones Cientificas Csic; Centro De Bioactivos Quim. Amines derived from 2-benzyl-5-nitroindazole with antiprotozoal properties against trypanosoma, leishmania and trichomonas. WO2019077174A1. 2018.
   Google Scholar
• Kantor S, Kennett RL, Waletzky E, et al. 1,3-Bis(p-chlorobenzylideneamino)guanidine hydrochloride (robenzidene): new poultry anticoccidial agent. Science. 1979;168(3929):373–374.
   Google Scholar
• Balouiri M, Sadiki M, Ibnsouda SK. Methods for in vitro evaluating antimicrobial activity: a review. J Pharm Anal. 2016;6(2):71–79.
   PubMed Web of Science ®Google Scholar
• Abraham RJ, Stevens AJ, Young KA, et al. Robenidine analogues as gram-positive antibacterial agents. J Med Chem. 2016;59(5):2126–2138. DOI:10.1021/acs.jmedchem.5b01797
   PubMed Web of Science ®Google Scholar
• Clark CG, Diamond LS. Methods for cultivation of luminal parasitic protists of clinical importance. Clin Microbiol Rev. 2002;15(3):329–341.
   PubMed Web of Science ®Google Scholar
• Stevens AJ, Abraham R, Young KA, et al. Antigiardial activity of novel guanidine compounds. Chem Med Chem. 2022;17(21):17. DOI:10.1002/cmdc.202200341
   Google Scholar
• Ogunniyi AD, Khazandi M, Stevens AJ, et al. Evaluation of robenidine analog NCL195 as a novel broad-spectrum antibacterial agent. PLoS ONE. 2017;12(9):12. DOI:10.1371/journal.pone.0183457
   Web of Science ®Google Scholar
• Pty Ltd N. Methods for treating protozoan infections. US10392363B2. 2019.
   Google Scholar
• Barbosa-Cabrera E, Moo-Puc R, Monge A, et al. In vitro and in vivo evaluation of Quinoxaline 1,4-di-N-oxide against Giardia lamblia. Lett Drug Des Discov. 2019;17(4):428–433.
   Web of Science ®Google Scholar
• Inst Politecnico Nacional. Use of quinoxaline 1,4-di-N-oxide ester derivatives for the treatment of giardiasis as anti-giardia-lamblia agents. MX2017012677A. 2017.
   Google Scholar
• Jilin University. Giardia chaperonin J inhibitor KNK437 and medical application thereof. CN112546045A. 2021.
   Google Scholar
• Khanna D, Bharti S. Luliconazole for the treatment of fungal infections: an evidence-based review. Core Evid. 2014;9:113–124.
   PubMedGoogle Scholar
• Niwano Y, Seo A, Kanai K, et al. Therapeutic efficacy of lanoconazole, a new imidazole antimycotic agent, for experimental cutaneous candidiasis in guinea pigs. Antimicrob Agents Chemother. 1994;38(9):2204–2206.
   PubMed Web of Science ®Google Scholar
• Pola Pharma Inc., Nihon Nohyaku Co., Ltd. Anti-tritrichomonas agent. WO2017168476A1. 2016.
   Google Scholar
• Matos APS, Viçosa AL, Ré MI, et al. A review of current treatments strategies based on paromomycin for leishmaniasis. J Drug Deliv Sci Technol. 2020;57:57.
   Web of Science ®Google Scholar
• Cheng Y, Honggang Z, Tao S. Application of paromomycin to preparation of medicine for treating Trichomonas vaginitis. CN105726552A. 2016.
   Google Scholar
• Guadalajara U. Use of terfenadine for the treatment of parasitic diseases. MX2019003675A. 2019.
   Google Scholar
• Palomo-Ligas L, Gutiérrez-Gutiérrez F, Ochoa-Maganda VY, et al. Identification of a novel potassium channel (GiK) as a potential drug target in Giardia lamblia: computational descriptions of binding sites. Peer J. 2019;7:2019.
   Web of Science ®Google Scholar
• King Abdulaziz University. Composition containing essential oils and plant extracts for treating vaginal infection and inflammation. US10154958B1. 2017.
   Google Scholar
• Sisto F, Carradori S, Guglielmi P, et al. Synthesis and biological evaluation of carvacrol-based derivatives as dual inhibitors of H. Pylori strains ags cell proliferation. Pharmaceuticals. 2020;13(11):1–21. DOI:10.3390/ph13110405
   Web of Science ®Google Scholar
• Batiha GES, Alkazmi LM, Wasef LG, et al. Syzygium aromaticum l. (myrtaceae): traditional uses, bioactive chemical constituents, pharmacological and toxicological activities. Biomolecules. 2020;10(2):10.
   Web of Science ®Google Scholar
• Beshbishy AM, Batiha GES, Yokoyama N, et al. Ellagic acid microspheres restrict the growth of Babesia and Theileria in vitro and Babesia microti in vivo. Parasites Vectors. 2019;12(1):12.
   PubMedGoogle Scholar
• Autonoma De Nuevo Leon U. Secondary fraction of the acetonic Syzygium aromaticum extract and its use as an amebicide and tricomonicide agent. MX2015008518A. 2015.
   Google Scholar
• Karuppannan K, Priyadharshini SD, Kokila K, et al. Phytopharmacological properties of Albizia species: a review. 2013.
   Google Scholar
• Lv JS, Zhang LN, Song YZ, et al. Biological activity exhibited by secondary metabolites of the Albizia julibrissin Durazz. pod. Int Biodeterior Biodegrad. 2011;65(1):258–264.
   Web of Science ®Google Scholar
• Chang JS, Liu HP, Cheng J, et al. Albizia julibrissin Ameliorates memory loss induced by Insomnia in Drosophila. Evid Compl Alternat Med. 2019;2019:2019.
   Web of Science ®Google Scholar
• Lu P, Zhang C, Zheng J, et al. A comparison review of Hehuan flowers and Hehuan bark on the traditional applications, phytochemistry and pharmacological effects. J Ethnopharmacol. 2023;303:116002.
   PubMed Web of Science ®Google Scholar
• Biospectrum Inc. An antibacterial composition containing the extracts of silk tree bark and the feminine cleanser composition comprising the same. KR20190092038A. 2019.
   Google Scholar
• Biospectrum Inc. A antibacterial composition containing the defatted Camellia’s seed extract and the feminine cleanser composition comprising the same. KR102172448B1. 2018.
   Google Scholar
• Qingdao Huangdao Hospital of Traditional Chinese Medicine. Chinese medicament for treating trichomonas vaginitis and preparation method. CN104740113A. 2015.
   Google Scholar
• Zibo Qidingli Patent Information Consulting Co Ltd. Traditional Chinese medicine suppository for treating trichomonas vaginitis. CN105106763A. 2015.
   Google Scholar
• Jiangsu Kangba Special Biological Engineering Co Ltd. Preparation method for pure Chinese herbal medicine antibacterial lotion special for gynecology. CN108434378A. 2018.
   Google Scholar
• Peng C. Traditional Chinese medicine for treating trichomoniasis intestinalis. CN106620112A. 2016.
   Google Scholar
• Puente-Rivera J, De Los Ángeles Ramón-Luing L, Figueroa-Angulo EE, et al. Trichocystatin-2 (TC-2): an endogenous inhibitor of cysteine proteinases in Trichomonas vaginalis is associated with TvCP39. Int J Biochem Cell Biol. 2014;54:255–265.
   PubMed Web of Science ®Google Scholar
• Turk V, Turk B, Guncar G, et al. Lysosomal cathepsins: structure, role in antigen processing and presentation, and cancer. Adv Enzyme Regul. 2002;42:285–303.
   PubMedGoogle Scholar
• Ct De Investigación Y De Estudios Avanzados Del I P N. Trichosystatin-2(TC-2) a cysteine proteinase inhibitor TvCP39 of Trichomonas vaginalis. MX2014010400A. 2016.
   Google Scholar
• Cock I, Mohanty IE. The chemotherapeutic potential of Terminalia ferdinandiana: phytochemistry and bioactivity. Pharmacogn Rev. 2012;6(11):29–36.
   PubMedGoogle Scholar
• Akter S, Netzel ME, Tinggi U, et al. Antioxidant rich extracts of Terminalia ferdinandiana inhibit the growth of foodborne bacteria. Foods. 2019;8(8):8.
   Web of Science ®Google Scholar
• Gunaguddya Pty Ltd. Treatment or prevention of giardiasis with a biologically active extract from terminalia ferdinandiana fruit. WO2017063017A1. 2017.
   Google Scholar
• Rising Phoenix Industries Pty Ltd. Terminalia ferdinandiana extract and products containing extract of terminalia ferdinandiana for antimicrobial or antibacterial applications. CA3062204A1. 2018.
   Google Scholar
• Agronomique Inst Nat Rech; Museum Nat Dhistoire Naturelle; Ecole Nat Veterinaire Dalfort. Compositions for the inhibition of Giardia lamblia. US10328132B2. 2019.
   Google Scholar
• Travers MA, Sow C, Zirah S, et al. Deconjugated bile salts produced by extracellular bile-salt hydrolase-like activities from the probiotic Lactobacillus johnsonii La1 inhibit Giardia duodenalis in vitro growth. Front Microbiol. 2016;7. DOI:10.3389/fmicb.2016.01453
   PubMed Web of Science ®Google Scholar